Natco Claims Sole Exclusivity For Ibrutinib Tablets

Claims US 180-Day Exclusivity On Four Strengths Of Imbruvica Rival

 
• By Dave Wallace

Natco says it will be entitled to 180-day exclusivity for four strengths of ibrutinib tablets in the US after receiving tentative FDA approval.

Natco Pharma Magnifying Glass
Natco says it will be entitled to 180-day exclusivity for four strengths • Source: Alamy

More from Generics

More from Products